A Four-week, Double-blind, Placebo-controlled, Randomized, Cross-over Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness.
Phase of Trial: Phase II
Latest Information Update: 06 May 2016
At a glance
- Drugs Solriamfetol (Primary)
- Indications Narcolepsy
- Focus Therapeutic Use
- Sponsors Aerial BioPharma
- 25 May 2012 Actual patient number (33) added as reported by ClinicalTrials.gov.
- 25 May 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 25 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.